retatrutide expanded access program Retatrutide: A deep dive Part 1 in a series covering what is and does as well as it's current status with the FDA Retatrutide: Evidence, Safety & Options

The FAERS database lists allodynia among the top 50 adverse reactions for tirzepatide specifically

Beyond nausea, the gastrointestinal side effect cluster includes diarrhea, vomiting, constipation, and decreased appetite, which is technically a desired effect but can become problematic at extreme levels

doi: 10.1111/dom.14089 231 SamsonSLGarberA

In September 2023, the FDA did update the semaglutide label to add ileus (a severe intestinal blockage) as a warning, demonstrating that the agency does act on emerging safety signals when the evidence supports it

doi: 10.1001/jama.2019.2942 56 PratleyRAmodAHoffSTKadowakiTLingvayINauckMet al

Herein, we report that pharmacologic stimulation of the cell GLP-1R activates cell PC1/3 and GLP-1 expression